131I标记抗CEA单抗预防人结肠癌肝转移的实验研究

目的 探索早期应用＾１３１Ｉ标记惮朱癌肝转移的可行性。方法 在建立人结肠腺癌习肝转移后，于１５ｍｉｎ、１０、２０ｄ经尾静注射＾１３１Ｉ标记抗ＣＥＡ单抗，于放射免疫疗法后４周和裸鼠死亡时，检查肝转移癌的数目、大小、瘤重、组织不和生存期。结果早期治疗组的肝转移癌数目、大小和瘤重均明显减小，瘤结节内有明显坏死，生存期延长。结论 早期应用＾１３１Ｉ标记抗ＣＥＡ单抗能有效地抑制肝转移癌的形成。

Study of prevention of liver metastasis of human colonic adenocarcinoma with 131I-labelled anti-CEA monoclonal antibodies in nude mice

Objective To study whether liver metastasis of colonic adenocarcinoma can be prevented with early administration of 131 I labelled anti CEA monoclonal antibodies (McAbs). Methods Nude mouse model of liver metastasis of colonic adenocarcinoma was established. 131 I labelled anti CEA McAbs were injected into nude mice 15 minutes, 10 days and 20 days after the animals were inflicted with liver metastasis of adenocarcinoma. 4 weeks later and when the the animals died, the number, size and weight of the hepatic metastatic lesions and the survival time of the animals were recorded and histopathological study of the metastatic foci was done.Results In the group with early administration of 131 I labelled anti CEA McAbs, the number, size and weight of the metastatic lesions in the liver were significantly decreased, obvious necrosis was found in the lesions and the survival time of the animals was prolonged.Conclusion 131 I labelled anti CEA McAbs can efficienctly inhibit formation of liver metastasis of human colonic adenocarcinoma.